TrialThe lancet. HIV2024

Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D

D2EFT Study GroupPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.